$\square$ 

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

1. Name and Address of Reporting Person

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									

pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		hours per response:	0.5	
2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC	5. Relationship of R (Check all applicabl Director	eporting Person(s) to Issuer e) 10% Owne		
ALXN				L

SQUINTO S (Last) C/O ALEXION 352 KNOTTE	(First) N PHARMAC	(Middle) EUTICALS IN	AL 3. D	LEXION PHA XN ] vate of Earliest Tran 02/2013					Carl applicable) 10% cf   Director 10% cf   Officer (give title Other   below) below   EVP, Chief Global Ops. Officer		(specify )	
(Street) CHESHIRE (City)	CT (State)	06410 (Zip)	4. If	Amendment, Date	of Origin	nal Fil	ed (Month/Day	6. Ind Line) X	ividual or Joint/Grou Form filed by On Form filed by Mo Person	e Reporting Per	son	
		Table I - No	on-Derivative	Securities Ac	quire	d, Di	sposed of	, or Be	eneficially	Owned		
Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) Code V Amount (A) or Price			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			

		(Month/Day/Year) 8)					-	Owned Following Reported	(I) (Instr. 4)	Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instit 4)
Common Stock, par value .0001 per share	08/02/2013		М		7,875 <sup>(1)</sup>	A	\$22.9	115,217	D	
Common Stock, par value .0001 per share	08/02/2013		М		6,250 <sup>(1)</sup>	A	\$42.66	121,467	D	
Common Stock, par value .0001 per share	08/02/2013		S		<b>4,9</b> 12 <sup>(1)</sup>	D	\$115.05 <sup>(2)</sup>	116,555	D	
Common Stock, par value .0001 per share	08/02/2013		S		2,963(1)	D	\$116.04 <sup>(3)</sup>	113,592	D	
Common Stock, par value .0001 per share	08/02/2013		S		4,858 <sup>(1)</sup>	D	<b>\$114.95</b> <sup>(4)</sup>	108,734	D	
Common Stock, par value .0001 per share	08/02/2013		S		1,392 <sup>(1)</sup>	D	\$116.12 <sup>(5)</sup>	107,342	D	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) ( Disp of (I	oosed D) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Purchase Common Stock	\$22.9	08/02/2013		М			7,875	04/28/2010	01/28/2020	Common Stock, par value \$.0001 per share	7,875	\$22.9	15,751	D	
Option to Purchase Common Stock	\$42.66	08/02/2013		М			6,250	05/02/2011	02/02/2021	Common Stock, par value \$.0001 per share	6,250	\$42.66	37,500	D	

### Explanation of Responses:

1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$114.77 - \$115.77. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$115.78 - \$116.78. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$114.76 - \$115.76. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

5. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$116.02 - \$117.02. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

#### Remarks:

/s/ Stephen Squinto

\*\* Signature of Reporting Person

08/02/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.